ANI Pharmaceuticals Inc. (NASDAQ: ANIP) announced the launch of Carbamazepine Extended-Release Capsules in 100 mg, 200 mg and 300 mg strengths. The capsules are a generic version of the reference drug Carbatrol.

The U.S. annual sales for Carbamazepine Extended-Release Capsules total approximately $65 million, based on February 2026 moving annual total IQVIA data, according to the company's statement.

"The launch of Carbamazepine Extended-Release Capsules, another limited competition product, highlights our continued commitment to improving patient access to essential medicines while maintaining the highest standards of quality and compliance," said Nikhil Lalwani, President and Chief Executive Officer of ANI.

ANI Pharmaceuticals is a biopharmaceutical company focused on developing, manufacturing and commercializing therapeutics through its Rare Disease, Generics and Brands business segments. The Princeton, New Jersey-based company operates in areas including ophthalmology, rheumatology, nephrology, neurology and pulmonology.